Clinical Trials in Oxford, England
9 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Germ Cell TumorChildhood Extracranial Germ Cell TumorExtragonadal Embryonal Carcinoma+27 more
Children's Oncology Group1,780 enrolled629 locationsNCT03067181
Recruiting
Phase 2
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Multifocal motor neuropathy
Dianthus Therapeutics36 enrolled26 locationsNCT06537999
Recruiting
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
Multiple System Atrophy
Ionis Pharmaceuticals, Inc.40 enrolled15 locationsNCT04165486
Recruiting
Phase 2Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis440 enrolled80 locationsNCT06943755
Recruiting
Phase 3
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Low-grade GliomaRapidly Accelerated Fibrosarcoma (RAF) Altered GliomaPediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.400 enrolled138 locationsNCT05566795
Recruiting
Phase 1Phase 2
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Xentria, Inc.94 enrolled34 locationsNCT05890729
Recruiting
Phase 2
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
Duchenne Muscular Dystrophy
Italfarmaco18 enrolled9 locationsNCT06769633
Recruiting
Phase 3
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Italfarmaco138 enrolled20 locationsNCT05933057
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707